Sydney-Based Pharmaxis Gets FDA Green Light On Bronchitol SPA

PERTH, Australia - Sydney-based Pharmaxis and the U.S. FDA reached an agreement on a Phase III registration trial of Bronchitol (mannitol) for treatment of bronchiectasis through the special protocol assessment process, which will form the basis of the company's efficacy claim, PharmAxis announced June 20